Therapeutics has moved to The Nucleus Building at
300 East Market Street, Suite 280,
Louisville, KY 40202.
ACT cleared to start Phase I in 1Q 2014 with novel small molecule, PFK158.
ACT completes an additional $5m captial raise to initiate and complete
Phase I trial with PFK158 a novel small molecule drug.